Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Esmolol-digoxin drug interaction.

D T Lowenthal1, R S Porter, R Achari

  • 1Likoff Cardiovascular Institute, Hahnemann University, Philadelphia, Pennsylvania.

Journal of Clinical Pharmacology
|August 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion·2023
Same author

A Phase I/II Study of Stereotactic Hypofractionated Once-weekly Radiation Therapy (SHORT) for Prostate Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019
Same author

Comparison of Epidemiology and Outcomes in Neuro-Oncology Between the East and the West: Challenges and Opportunities.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019
Same author

Continuous hyperfractionated accelerated radiotherapy using modern radiotherapy techniques for nonsmall cell lung cancer patients unsuitable for chemoradiation.

Indian journal of cancer·2017
Same author

Actual gains in dosimetry and treatment delivery efficiency from volumetric modulated arc radiotherapy for inoperable, locally advanced lung cancer over five-field forward-planned intensity-modulated radiotherapy.

Indian journal of cancer·2017
Same author

High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.

Clinical oncology (Royal College of Radiologists (Great Britain))·2017
Same journal

Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two-Injection Start Regimen with Aripiprazole Once-Monthly Long-Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder.

Journal of clinical pharmacology·2026
Same journal

External Evaluation of Population Pharmacokinetic Models for Factor VIII in Chinese Patients with Hemophilia A.

Journal of clinical pharmacology·2026
Same journal

How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation.

Journal of clinical pharmacology·2026
Same journal

Genome Sequencing Enhances Precision and Clinical Utility of Pharmacogenetic Data Compared to Arrays.

Journal of clinical pharmacology·2026
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
See all related articles

Concurrent administration of esmolol (a beta-blocker) and digoxin showed no significant impact on esmolol pharmacokinetics. However, digoxin AUC increased slightly, suggesting caution when combining these drugs.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Interactions

Background:

  • Esmolol is a cardioselective, short-acting beta-blocker.
  • Digoxin is a cardiac glycoside used for heart failure and arrhythmias.
  • Concurrent administration of these drugs requires understanding potential interactions.

Purpose of the Study:

  • To investigate the pharmacokinetic interaction between esmolol and digoxin.
  • To assess the impact of concurrent administration on steady-state conditions.

Main Methods:

  • Open-label, baseline-controlled study.
  • Involved 11 healthy male subjects.
  • Measured pharmacokinetic parameters of esmolol and digoxin during concurrent administration.

Related Experiment Videos

Main Results:

  • Digoxin did not significantly alter esmolol's steady-state concentration, half-life, or clearance.
  • Esmolol did not affect digoxin's peak concentration or time to peak.
  • A statistically significant, though small, increase in digoxin's AUC was observed during esmolol infusion (P < .05).
  • No clinically significant changes in heart rate, blood pressure, or PR intervals were noted.

Conclusions:

  • Digoxin does not influence esmolol pharmacokinetics.
  • Concurrent use of esmolol and digoxin may lead to a minor increase in digoxin serum concentration.
  • Caution is advised during the combined administration of esmolol and digoxin.